中国实用医药
中國實用醫藥
중국실용의약
CHINA PRACTICAL MEDICAL
2015年
28期
10-12
,共3页
功能性消化不良%氟哌噻吨美利曲辛片%莫沙必利%焦虑症
功能性消化不良%氟哌噻噸美利麯辛片%莫沙必利%焦慮癥
공능성소화불량%불고새둔미리곡신편%막사필리%초필증
Functional dyspepsia%Flupentixol and melitracen tablets%Mosapride%Anxiety disorder
目的：观察氟哌噻吨美利曲辛片(黛力新)联合莫沙必利对老年人功能性消化不良(FD)的疗效。方法收集(FD)患者486例，进行焦虑评定(SAS)， SAS 评分总粗分>40分为焦虑症，其中焦虑症患者351例(A 组)，未患焦虑症患者135例(B 组)，将 A、B 两组患者按照数字法分别随机分两组， A1组(175例)、B1组(67例)给予莫沙必利治疗， A2组(176例)、B2组(68例)给予莫沙必利联合黛力新治疗，治疗4周后观察疗效。结果FD 患者中焦虑症发生率为72.22%(351/486)，治疗后， A2组患者比A1组患者，其疗效更为显著(93.75% VS 23.43%)，两组比较差异有统计学意义(P<0.05)；B2组患者与 B1组患者比较并未收到良好效果(36.76% VS 35.82%)，两组比较差异无统计学意义(P>0.05)；A1组患者其疗效明显低于 B1组患者(23.43% VS 35.82%)，两组比较差异有统计学意义(P<0.05)。结论FD 患者中患焦虑症的患者比例高；黛力新对合并有焦虑症的 FD 患者有疗效，对于未合并有焦虑症的 FD 患者无效，因此对于 FD 患者是否使用黛力新治疗要依据焦虑评定。
目的：觀察氟哌噻噸美利麯辛片(黛力新)聯閤莫沙必利對老年人功能性消化不良(FD)的療效。方法收集(FD)患者486例，進行焦慮評定(SAS)， SAS 評分總粗分>40分為焦慮癥，其中焦慮癥患者351例(A 組)，未患焦慮癥患者135例(B 組)，將 A、B 兩組患者按照數字法分彆隨機分兩組， A1組(175例)、B1組(67例)給予莫沙必利治療， A2組(176例)、B2組(68例)給予莫沙必利聯閤黛力新治療，治療4週後觀察療效。結果FD 患者中焦慮癥髮生率為72.22%(351/486)，治療後， A2組患者比A1組患者，其療效更為顯著(93.75% VS 23.43%)，兩組比較差異有統計學意義(P<0.05)；B2組患者與 B1組患者比較併未收到良好效果(36.76% VS 35.82%)，兩組比較差異無統計學意義(P>0.05)；A1組患者其療效明顯低于 B1組患者(23.43% VS 35.82%)，兩組比較差異有統計學意義(P<0.05)。結論FD 患者中患焦慮癥的患者比例高；黛力新對閤併有焦慮癥的 FD 患者有療效，對于未閤併有焦慮癥的 FD 患者無效，因此對于 FD 患者是否使用黛力新治療要依據焦慮評定。
목적：관찰불고새둔미리곡신편(대력신)연합막사필리대노년인공능성소화불량(FD)적료효。방법수집(FD)환자486례，진행초필평정(SAS)， SAS 평분총조분>40분위초필증，기중초필증환자351례(A 조)，미환초필증환자135례(B 조)，장 A、B 량조환자안조수자법분별수궤분량조， A1조(175례)、B1조(67례)급여막사필리치료， A2조(176례)、B2조(68례)급여막사필리연합대력신치료，치료4주후관찰료효。결과FD 환자중초필증발생솔위72.22%(351/486)，치료후， A2조환자비A1조환자，기료효경위현저(93.75% VS 23.43%)，량조비교차이유통계학의의(P<0.05)；B2조환자여 B1조환자비교병미수도량호효과(36.76% VS 35.82%)，량조비교차이무통계학의의(P>0.05)；A1조환자기료효명현저우 B1조환자(23.43% VS 35.82%)，량조비교차이유통계학의의(P<0.05)。결론FD 환자중환초필증적환자비례고；대력신대합병유초필증적 FD 환자유료효，대우미합병유초필증적 FD 환자무효，인차대우 FD 환자시부사용대력신치료요의거초필평정。
Objective To observe curative effect of flupentixol and melitracen tablets (deanxit) combined with mosapride for senile functional dyspepsia (FD). Methods There were 486 FD patients in self-rating anxiety scale (SAS), and anxiety disorder had SAS > 40 points. There were 351 cases with anxiety disorder (group A) and 135 cases without anxiety disorder (group B). Groups A and B were divided by random number table into two groups respectively. Groups A1 (175 cases) and B1 (67 cases) received mosapride for treatment, and groups A2 (176 cases) and B2 (68 cases) received deanxit combined with mosapride for treatment. Curative effects were observed after 4 weeks of treatment. Results Incidence of anxiety disorder in FD patients was 72.22%(351/486). After treatment, group A2 had much better curative effect than group A1 (93.75% VS 23.43%), and their difference had statistical significance (P<0.05). Group B2 had similar curative effect as group B1 (36.76%VS 35.82%), and the difference between the two groups had no statistical significance (P>0.05). Group A1 had obviously lower curative effect than group B1 (23.43% VS 35.82%), and their difference had statistical significance (P<0.05). Conclusion Anxiety disorder has high incidence in FD patients. Deanxit can provide precise effect for FD complicated with anxiety disorder patients, while it is ineffective for FD patients without anxiety disorder. Therefore, implement of deanxit in FD patients should depend on their anxiety status.
